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Adrenal melanoma first reported by Kniseley et al in 1946 is a relatively aggressive tumor 
affecting the middleaged adults.1 The longest postoperative survival reported is 46 
months.2 In cases with adrenal metastases originating from a primary melanoma source, 
prognosis is worse with a median overall survival of 6 months.3 Adrenal glands are the sixth 
most common site of distant metastases from melanoma (after lymph nodes (73.6%), lungs 
(71.3%), liver (58.3%), brain (54.6%) and bone (48.6%)).4 
It manifests itself with flank pain and usually renal involvement is detected at the time of 
diagnosis. Additionally, distant lymph node metastasis could also be detected. Absence of 
previous unilateral adrenal gland involvement, presence of pigmented lesions without any 
signs of endocrine disorder, and negative immunohistochemical endocrine markers are 
typical characteristics of primary malignant melanoma of the adrenal gland. Presence of an 
occult primary lesion should also be excluded by autopsy.   
Pluripotent neural crest cells are localized within adrenal gland medulla. They are 
precursors of melanocytes, neurons, glial cells of the peripheral nervous system, and adrenal 
chromaffin cells. Under the influence of microenvironment, and various growth factors, 
these multipotent cells might transform into different cell types.5 
Differential diagnosis is difficult to establish based on the radiological criteria. Melanomas 
do not usually display disease specific signs. Computerized tomography has been the 
preferred diagnostic tool for the evaluation of adrenal glands. Rajaratnam et al concluded 
that an adrenal mass greater than 5 cm in diameter, with central or irregular areas of 
necrosis/hemorrhage (and no lipomatous component) is a characteristic metastasic focus 
from malignant melanoma.4 18FFDG PET is a wellestablished diagnostic tool for restaging.6 
Histopathologically, it is very hard to discriminate adrenal melanoma and 
pheochromocytoma. Melanin and melaninlike pigment can be detected in 
pheochromocytomas.7 Some authors suggest that adrenal melanoma takes origin from 
pheochromocytoma, and thus it should be termed as melanotic malignant 
pheochromocytoma.8 However, some others do not agree this opinion, and suggest that 
these tumors should have diverse origins.9 Differential diagnosis between adrenal 
melanoma and pheochromocytoma could be established using immunohistochemical 







specific enolase and neurosecretory granules (under electron microscopy) are detected only 
in pheochromocytomas.2,9,10 
Since these tumors adhere to the adjacent kidney, nephroadrenelectomy is the preferred 
surgical treatment modality. Liatsikos et al performed the first laparoscopic adrenalectomy 
in a patient with primary adrenal malignant melanoma.10 Because of its rare occurrence, a 
consensus has not yet been established with respect to adjuvant therapies such as 
radiotherapy1 or chemotherapy with dacarbazine.11  Adrenal metastases of melanoma 
provide additional evidence of systemic disease with an overall poor prognosis. For these 
patients, systemic therapy is usually preferred. Mittendorf et al suggested the option of 
adrenalectomy for those patients with no or limited extraadrenal disease.12 
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	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Melanoma formed by melanin producing cells accounts for 68,000 newly reported cases, and 
is responsible for 8600 deaths annually in the United States.13 It ranks sixth among the most 
frequently encountered malignancies in the UK, and malignant melanoma is most often 
encountered between the ages of 15 and 34 years.14 Its incidence over the last decade has 
increased faster than the other types of malignancies.15 
Renal metastasis of melanoma is rarely seen entity among the renal metastatic tumors. 
Accordingly, it is reported that kidney involvement in patients with malignant melanoma 
was around 24% to 50% of the cases.16 In a seriesconsisting  of 142 cases of metastatic 
genitourinary tract melanomas reported by Abeshouse, the primary cancer source was skin 
in 80 % of the cases.17 However, renal involvement unrelated to any primary pigmented skin 
lesion was also reported.18 Levin et al. reported a case of an isolated renal metastasis 20 
years after initial diagnosis and treatment secondary to an ocular melanoma occurring.19 
Renal metastases secondary to cutaneous melanomas have been detected as multiple 
microscopic or millimetric foci. They usually progress insidiously and tend to invade 
adjacent perirenal space. They are highly vascularized. Boughan reported a metastatic case 
of melanoma localized in the upper renal pole and infiltrated the inferior vena cava (IVC).18 
Anecdotal reports of renal vein invasion by the tumor thrombi arising from secondary 
metastatic renal tumors have been encountered in the literature. Indeed, Klatte presented a 
case of renal metastasis of a malignant melanoma in which renal vein had been occluded by 
a tumor thrombus.20 It was also underlined that renal metastases of malignant melanoma 
usually reflect endstage renal disease.20 
Transmission of donor malignancies to organ transplant recipients is a rare complication of 
transplantation. Malignant melanoma is one of the most commonly reported donorderived 
malignancies. The mechanism of transmission of melanoma from the donor to recipient is 
unknown. Circulating tumor cells or dormant micro metastases residing in the organ 
parenchyma has been blamed for this transmisssion.14 In the literature, there are 15 case
reports of melanoma transferred from donor organs to 28 recipients. The organs were 
transplanted in the range of six months to 16 years after the donors had undergone 
melanoma surgery.2124 MacKie et al had underlined that none of the patients with invasive 
melanoma should ever be an organ donor because of the possibility of the late and ultralate 
recurrences in melanoma.21 It has been estimated that between 0.98% to 6.7% of melanomas 
recur 10 years after the initial treatment.25 Its ulcerated nature and depth of cutaneous 
infiltration are risk factors in favor of  recurrences  and also the distant recurrences were 







Biological behavior of malignant melanoma is quite complex.  Recurrences might be seen 
years after remission and it is believed that recurrences have been associated with re
activation of dormant cells. The maintenance of dormancy is hypothesized to be the result of 
a proficient immune system. Therefore, tumor cells remain dormant in an 
immunocompetent host. However immunosuppressed status of the patient as seen after 
transplantation serves as an ideal environment for the reactivation of the dormant cells.27 
Radiological differentiation of renal metastases from renal cell carcinoma (RCC) is quite a 
complicated issue. The sensitivity of 18FFDG PET that is routinely used for the diagnosis of 
advanced disease, visceral, deep softtissue and lymph node involvement is quite low for 
the detection of earlystage malignant melanoma.28 PET which uses a new analogue of 
fluoronicotinamide i.e. 18FMEL050 has a higher specificity, and sensitivity.29 Definitive 
diagnosis of melanoma is established through cytological examination of the renal biopsy 
specimen. In malignant melanoma, cellular shapes and patterns might show variations 
depending of the originator tissue. Cytological features of a melanoma resemble those of the 
other poorly differentiated neoplasms like carcinomas, lymphomas, and sarcomas.30 For 
diagnostic purposes immunocytochemical staining is used. In clinical practice, mostly S100 
protein, and HMB45 antibodies, and recently found MART1 melanocyte antigens have 
been used.30,31 
S100 protein is a calcium binding protein which had been isolated from brain tissue, and it is 
90% sensitive for melanoma. However its sensitivity might drop to 70 % with respect to its 
discriminative potential between malignant melanomas, and spindle cell lesions with 
similar cytomorphologic features. In addition, primary renal tumors also stain with 
melanocytic markers. As previously demonstrated by Lin et al, 14.8 % of primary RCC’s 
were stained positively with   S100 protein.32 
HMB45 staining is relatively more specific for melanoma, and it is positive in 96.8 % of the 
cases. However its sensitivity decreases in spindlecell and desmoplastic variants of 
melanomas, because of their lack of reactivity to HMB45 staining. This phenomenon has led 
to the development of a more sensitive, and specific novel monoclonal antibody. MART1 is 
a melanocytic antigen encoding gene which is only expressed in skin, retina, and 
melanocytic cells.  MART1 possesses 95 % sensitivity, and 97 % specificity for the detection 
of melanomas. However sensitivity of MART1 reportedly decreases in the detection of 
spindlecell, and desmoplastic variants of melanoma. 
Angiomyolipomas originating from blood vessels, smooth muscle, and adipose tissue, and 
primary renal tumors carrying a translocation domain  on t(6;11)(p21.1;q12) chromosome of 
TFEB ALPHA gene may also stain positively for melanin proteins. Epithelioid and spindle 
cell angiomyolipomas have a staining pattern for melanomaspecific, HMB45 marker.33 
Translocation of ALPHA gene on chromosome on to intron 1 on  TEFB located chromosome 
6 is related to a RCC subgroup with pleomorphic histological characteristics, and they stain 
positively for melanocytic markers such as  HMB45, and MelanA.34 
Malignant melanoma is an immunologically active disease. Various forms of systemic 
immunotherapy such as Bacille Calmette Guerin (BCG), interferonalpha and allogenic 
tumor vaccines have demonstrated significant improvements in overall and diseasefree 
survival rates.3538 Currently, recommended treatment modalities for donorrelated 
melanoma transmission consist of cessation of immunosuppressive therapy, achievement of 
rejection, and removal of the donor organ. In addition adjuvant chemotherapy or interferon











Ureteral malignant melanoma is a rarely seen entity. Generally it emerges as a metastatic 
focus. In the English medical literature limited numbers of ureteral malignant melanomas 
have been reported.  Clinically, it manifests itself with symptoms of colicky pain. 
Radiologically, hydronephrosis, hydroureteonephrosis, and filling defects are seen in the 
upper urinary tract depending on the level of ureteral involvement. Ureteral mass lesion is 
verified by ureteroscopic examination. 
Definitive diagnosis is established after immunohistochemical examination of the biopsy 
material. A clearcut consensus on its management is lacking due to its rarity. Tumor can 
spread to all parts of the urinary tract after URS or DJ stenting. In their casepresentation, 
Gakis et al. proposed a management protocol for ureteral malignant melanoma in 
consideration of literature findings.4043 Accordingly, they recommended 
nephroureterectomy and regional lymphadenectomy for unilateral upper urinary tract 
involvement. Positive surgical margins, positive lymph nodes or depth of primary 
cutaneous tumor exceeding 1.5mm necessitate administration of adjuvant chemotherapy 
(dacarbazine). Local recurrences could be managed with resection and chemotherapy. In the 
presence of bilateral resectable lymphometastatic lesions, partial ureterectomy, and bilateral 
regional lymphadenectomy should be employed. Besides, adjuvant chemotherapy is 
recommended. For nonresectable lesions, radiation therapy and chemotherapy are among 






Lower urinary system contains bladder, urethra, and prostate gland in men.  Symptoms of 
lower urinary tract diseases generally mimic each other. In older men, benign prostatic 
hyperplasia triggers symptoms such as dysuria, urgency, frequency, nocturia. On the other 
hand, overactive bladder is another frequently seen entity in women. Melanoma also 




Despite rarity of primary malignant melanoma of the bladder, genitourinary system 
metastases of the bladder melanoma have a relatively higher incidence. Renal (45 %), and 
vesical (18 %) metastases had been found in patients deceased because of melanoma.44 
Therefore, discrimination between primary and metastatic melanomas of the bladder is 
crucial. Stein45 and Ainsworth46 established some diagnostic criteria for primary bladder 
tumors: (1) absence of any previous skin lesion (2) or cutaneous malignant melanoma (3) or 
primary visceral malignant melanoma (4) recurrence pattern showing consistency with the 
primary tumor diagnosis (5) atypical melanocytes at the tumor margin on microscopic 
examination. In the literature including the most recent case reported by Siroy AE et al.the 
number of  cases with primary melanoma of the bladder amounts to 20.44,47 However all the 
cases reported in the literature as primary melanoma of the bladder do not fit in these 
criteria of primary vesical melanoma. 
Its initial clinical presentation is hematuria, as seen in other types of bladder carcinomas. 
However hematuria is a clinical sign of locally advanced disease.1Some patients present 
with lower urinary tract symptoms. During advanced stages of the disease, clinical 







Cystoscopy is the primary diagnostic modality. Cystoscopy usually reveals a dark 
pigmented mass with varying dimensions. Mucosal layer surrounding the tumoral mass has 
a dark brown appearance, while the mucosa distant from the lesion has a pinkish white 
color.46 Diagnosis is made with histopathological examination of the biopsy material. 
Immunohistochemical studies shorten and facilitate diagnostic workup. 
Despite treatment alternatives including transurethral resection, partial and radical 
cystectomy, radiotherapy, immunotherapy, and chemotherapy, overall it has a poor 
prognosis. Transurethral resection is curative for lesions restricted to epithelium, and 
actually the definitive cure could be achieved by radical cystectomy.44,47 In cases where 
surgery is contraindicated or chemotherapy is not tolerated because of its side effects, 
radiation therapy and immunotherapy with interferonalpha can be applied.47 Despite all 
these treatment alternatives, the prognosis is poor and the patients are generally lost within 





In general, prostatic melanoma symptomatically resembles benign prostatic hyperplasia. 
First, obstructive signs and symptoms are detected in these patients. Sometimes irritating 
symptoms might be more prominent and they may mimic urinary tract infections or 
overactive bladder. This symptomatic ambiguity may lead to misdiagnosis and delay 
correct therapy. Therefore, patients with refractory symptoms to treatments or improper 
features of patients for suspected diseases such as young patient with BPH symptoms must 
warn us to overlook another extraordinary disease.48 Prostatic melanoma is a rare neoplasm 
of prostate and must be kept in mind in the differential diagnosis after a thorough  
evaluation. Rare incidence of primary prostatic malignant melanoma in clinical practice, 
early diagnosis and differentiation of primary malignant melanoma from epithelial cancer 
are extremely important considerations, because while prostate cancer can be treated as a 
chronic disease for years, malignant melanoma of the prostate can rapidly progress to 
terminal stage with a high mortality.4951 
If one suspects malignancy after digital rectal examination, computerized tomography 
and/or transrectal ultrasound as well as radical prostatectomy and if needed lymph node 
dissection should be added to the diagnostic workup. Alternatively, transurethral resection 
or transrectal ultrasound guided prostate biopsy could be performed to establish a 
diagnosis. Notably, not only surgical approach but also chemotherapeutic treatment plays a 




Primary malignant melanoma of urethra is a rare entity, representing less than 1% of all 
melanoma and 4% of urethral cancers.52 Rarity and difficulty in diagnosis results in a fairly 
late detection and poor prognosis. Noteworthy, urethral malignant melanomas are generally 
associated with immunocompromised conditions including alcoholism, dialysis, and poor 
selfcare.  
Patients with urethral malignant melanoma admit to the clinics with various complaints. 
Protruding mass is s one of the most common clinically observed because distal urethra is 
involved more frequently than the other parts.53,54 Lower urinary system complaints 







sometimes mimic benign prostatic hyperplasia or chronic prostatitis. Unfortunately, only 
after medical treatment fails in these patients, cancer diagnosis could be established with a 
significant delay.55 Additionally, hematuria and urethral discharge are other complaints in 
patients with urethral melanoma.   
Routine physical examination of urogenital system and inguinal region must be performed 
meticulously as well since a complete examination may sometimes provide crucial clues to 
reach final diagnosis. Direct visual detection of tumor mass in females is frequently easy and 
straightforward because of shorter length of female urethra.  Likewise, most of the urethral 
tumor mass located in the distal part with protrusion could easily be detected.  
Unfortunately, at the time of admission of the patients, there is no available specific serum 
tumor markers like 5Scysteinyldopa, an intermediate metabolite of melanin biosynthesis 
which is  used in postoperative melanoma followup, high in chronic renal failure no urine 
tests or imaging methods to detect the exact nature of the lesion and neoplastic features in 
early period. After the diagnosis is verified, evaluation of recurrence, lymph node and other 
organ involvement must be investigated using ultrasound, computerized tomography, 
magnetic resonance imaging or PET scan. 
Although atypical pigmented melanocytic cells might be seen in cytological examination, 
this clue should increase the suspicion of melanoma and lead to a more meticulous cancer 
workup at this point. Unfortunately, cytology sometimes could not provide any evidence of 
cancer. However, even in cases of inconclusive cytology, false negativity must always be 
kept in mind. Histopathological examination of specimens is performed based on the 
cellular differentiation, pleomorphism, solidity and grade of tumor according to WHO’s 
schema. Additionally, diagnosis is supported by immunostainings with a specific marker 
for melanoma (antiVimentin +, Protein S100 +, HMB – 45 +, Melan A +; AE1/AE3 +,  
CD 20 +).   
Although the optimum therapy has not yet been established, considering the rarity of the 
urethral melanoma, surgical intervention plays the major role in first line therapy. 
Melanoma spreads to the other organs via the lymphatic drainage. The urethra, particularly 
the distal urethra including fossa navicularis and urethral meatus are the most common 
locations and about 30% of patients already harbor metastasis at the time of diagnosis with 
dangerous boundaries with regards to the depth of invasion and size of the tumor mass.57,58 
While cancers of the anterior urethra preferentially infiltrate into superficial inguinal lymph 
nodes,  those involving the posterior urethra generally infiltrate into pelvic lymphatic 
channels.57 However, the presence or absence of lymph node metastasis is the most 
significant prognostic factor for survival, as survival rates are approximately halved by the 
presence of nodal metastasis. Consequently, melanoma’s aggressiveness, higher stage, and 
palpable lymphadenopathy require lymphadenectomy. However, unnecessary 
lymphadenectomy may result in lymphedema, pain, infections and other complication.  For 
this reason, lymphadenectomy must be standardized especially for those patients with: 
1. Palpable adenopathy (extended lymphadenectomy superficial and deep inguinal LND) 
2. Lesions more than 1 cm in size 
3. Presence of ulceration 
4. Clark’s level IVV  
Modified lymphadenectomy must be performed for all anterior urethral lesions other than 
Tis.59 Local relapses and systemic metastases frequently develop in the early postoperative 







alone is not adequate to control local relapses and systemic metastases, thus adequate 
postoperative adjuvant therapy is required to prevent the relapse and progression of the 
disease. Combined use of multiple chemotherapeutic agents such as cisplatin, dacarbazine, 
carmustine and tamoxifen has been recommended in lieu of monotherapy.60 However; even 
combination regimens do not satisfactorily increase the survival rates of patients with 
metastatic melanoma. Immunotherapy based on αinterferon and tumor vaccines has also 






These organs are external organs of male genital system. Primary malignant melanoma of 
these organs will be presented together with the metastatic ones under the same title 
because of their close relation. 
Penile melanomas usually present as pigmented macule, papule, or ulcerations with an 
irregular border; however, it might be unpigmented as well. It is typically found on the 
glans penis and less often on the prepuce. The American Joint Committee on Cancer system 
classifies cutaneous melanomas based on the depth of invasion (Clark staging) and tumor 
thickness (Breslow level, direct measurement). Hematogenous metastases occur through the 
vascular structures of the corporal bodies; and lymphatic spread to the regional lymphatic 
ilioinguinal nodes occurs by lymphatic flow.62  Scrotal melanoma  has also been detected 
with similar appearance of penile melanoma. Testicular, epididymis and seminal vesicle 
malignant melanomas are metastatic and display no symptoms until before reaching 
sizeable masses so as to be detected during physical examination, and are mostly detected at 
autopsies.63 
Definitive diagnosis of penile, scrotal and testicular melanoma could only be established 
histopathologically. However, imaging methods such as CT or MRI may help to delineate 
the boundaries of the lesion and macroscopical invasion to neighboring structures. After 
treatment, nuclear scintigraphy is useful for whole body scanning. Starting from early 
1990s as an adjunct to followup scanning protocol, sentinel lymphadenectomy using 
radio colloid mapping and dye localization for melanoma has been described. This 
technique is minimally invasive and sensitive enough to detect the relevant nodes in the 
correct nodal location without complete dissection. When the sentinel node is negative for 
metastatic disease the incidence of micro metastases in the remaining structure is less than 
1% to 2%.64 
In patients with penile lesions less than 1.5 mm deep, less aggressive treatment with local 
excision has been effective.6567 However, the risk of metastasis to regional lymph nodes 
with a resultant poor outcome is high. Considering the rarity of the disease, aggressive 
treatment in selected patients with penectomy or partial penectomy of the primary tumor 
with bilateral lymph node dissection has been recommended.65 Despite aggressive 
surgical treatment and chemotherapy, patients with metastatic disease have a poor 
prognosis. 
Patients with penile melanoma of stage III or more have an extremely poor prognosis; the 
5year and 10year survival rates of Japanese patients with stage IIIB melanoma are 40% 
and 38%, respectively.68 Penile malignant melanoma patients with positive lymph nodes 
carry a poor prognosis of less than 2 years of mean survival.65 According to the guidelines 
for treatment of patients in each stage, in addition to radical dissection of regional lymph 







for patients with stage III melanoma. 5DAVFeron therapy dacarbazine, ACNU 
(nimustine hydrochloride), VCR (vincristine sulfate), plus interferonb is recommended as 
a postoperative adjuvant therapy for patients with stage IIIB melanoma. Therapy can 
significantly improve the 5year survival rate of patients with malignant melanoma 
compared to the DAV therapy alone.69 The Feron therapy, in which interferonb (300 ¥ 104 
IU) is locally injected into the wound area for 10 days, is recommended as an adjuvant 
therapy for patients with stage I–II melanoma. Scrotal melanoma is treated with 
orchiectomy and lymphadenectomy; and additional chemotherapy must also be 
planned.70    
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